Short answer
CVRx, Inc. (CVRX) filed an 8-K current report with the SEC on August 6, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). CVRx announced financial results for Q2 ended June 30, 2026.
CVRx, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- CVRx announced financial results for Q2 ended June 30, 2026
- Full operating results and financial metrics are contained in Exhibit 99.1
- Results release dated August 6, 2026, providing the next quarterly update for investors
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $15.7M, up 16%; U.S. revenue $14.8M, up 21%, indicating continued Barostim adoption
- U.S. revenue units rose to 466 from 391; active implanting centers reached 258 from 240
- Gross margin expanded to 87% from 84%, while net loss narrowed to $14.0M from $14.7M
- Full-year revenue outlook reset to $58.0M-$60.0M, reflecting fewer territories, lower productivity, and payer challenges
- Humana coverage effective May 1 expands reimbursement access across approximately 5.2M Medicare Advantage members in 46 states
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CVRx, Inc. 8-K filings
Get the next CVRX 8-K as it lands
Follow CVRX for push alerts, or ask the research agent what this filing means.